Hello AAPS Community Members,
The upcoming NAber working group (Tuesday, 21 October 2025, 12:00 - 12:45 EST), will host Dr. Kelly Pham of Merck who has kindly offered to share a presentation recently shared at the Immunogenicity and Bioassay Summit on the challenges of developing a cell based NAb assay for a GLP-1 agonist. Details are below.
A Strategic Approach to Cell-Based Neutralizing Antibody Assays for Bispecific Peptide
Innovative multiplexed cell-based assays were designed to detect neutralizing antibodies (NAbs) against efinopegdutide, a dual GLP-1R/GCGR agonist peptide drug. Multiple assay formats were rigorously evaluated to develop assays that detect NAbs against the drug and its endogenous peptides, which carry the highest immunogenicity risk. Our multiplexing approach significantly reduces resource use, accelerates validation, and we established two cut points to effectively address matrix interference.
Many thanks again to Kelly for her willingness to share experience and learnings in this project. For anyone interested in joining the NAber Working Group, please contact @Lynn Kamen, @Weifeng Xu, or myself. Thanks again, looking forward to hearing from current and new members.
Thank you,
Andrew
------------------------------
Andrew Asberry
Director, Oncology Bioanalytical Strategy Lead
AstraZeneca, Plc
Gaithersburg MD
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------
Andrew Asberry
Director, Oncology Bioanalytical Strategy Lead
AstraZeneca, Plc
Gaithersburg MD
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------